Infinity to Participate in Oppenheimer’s Fall Healthcare Life Sciences and MedTech Summit and the 3rd Annual Macrophage-directed Therapies Summit

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that the Company will participate in Oppenheimer’s Fall Healthcare Life Sciences and MedTech Summit and at the 3^rd Annual Macrophage-directed Therapies Summit.

Presentation details can be found below:

• Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
  
  Format: Live presentation and 1-on-1 meetings
  
  Date and Time: September 20^th at 1:15pm ET; 1-on-1 meetings September 20 - 22
  
  Webcast Link: https://wsw.com/webcast/oppenheimer16/infi/2761042

• 3^rd Annual Macrophage-directed Therapies Summit
  
  Format: Seminar and panel discussion
  
  Title: Evaluating the Synergistic Potential of Combination with Other Frontline Treatments to Distinguish the Best Combination Approach
  
  Date and Time: September 30^th, 4:00pm ET
  
  Registration Link: https://macrophage-directed-therapies.com/take-part/register/

The presentations and archived webcasts can be accessed in the Investors/Media section of Infinity's website at www.infi.com and will be available on Infinity's website for 30 days following the event.

About Infinity and Eganelisib

Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo^® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq^® and Abraxane^® in front-line TNBC and in combination with Tecentriq and Avastin^® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil^® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo^® is a registered trademark of Bristol Myers Squibb.

Tecentriq^® is a registered trademark of Genentech, Inc.

Abraxane^® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.

Avastin^® is a registered trademark of Genentech, Inc.

Doxil^® is a registered trademark of Baxter Healthcare Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005168/en/